Investing.com - Financial Markets Worldwide

Lyra Therapeutics Inc (LYRA)

NASDAQ
Currency in USD
6.700
-0.190(-2.76%)
Closed·
After Hours
6.520-0.180(-2.69%)
·
LYRA Scorecard
Full Analysis
RSI suggests the stock is in oversold territory
Earnings results expected in 3 days
LYRA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
6.5607.080
52 wk Range
3.81037.500
Key Statistics
Edit
Prev. Close
6.89
Open
6.73
Day's Range
6.56-7.08
52 wk Range
3.81-37.5
Volume
13.04K
Average Volume (3m)
677.25K
1-Year Change
-56.45%
Book Value / Share
2.94
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LYRA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
23.000
Upside
+243.28%
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 14
Quickly burning through cash
Unlock InvestingPro

Lyra Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Lyra Therapeutics Inc Company Profile

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
30
Market
United States

Compare LYRA to Peers and Sector

Metrics to compare
LYRA
Peers
Sector
Relationship
P/E Ratio
−0.1x0.0x−0.5x
PEG Ratio
−0.450.060.00
Price/Book
2.8x0.0x2.6x
Price / LTM Sales
9.0x1.4x3.3x
Upside (Analyst Target)
243.3%230.5%43.5%
Fair Value Upside
Unlock25.4%6.8%Unlock

Analyst Ratings

0 Buy
4 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 23.000
(+243.28% Upside)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
-6.50 / -0.12
Revenue / Forecast
183.00K / 102.35K
EPS Revisions
a
a
Unlock
Last 90 days

LYRA Income Statement

People Also Watch

Bitmine Immersion Tech
51.43
BMNR
+24.59%
Sarepta
18.23
SRPT
+1.50%
Vor Biopharma
2.070
VOR
0.00%
Robin Energy
1.86
RBNE
+6.90%
Sharplink Gaming
23.920
SBET
+2.40%

FAQ

What Stock Exchange Does Lyra Trade On?

Lyra is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Lyra?

The stock symbol for Lyra is "LYRA."

What Is the Lyra Market Cap?

As of today, Lyra market cap is 10.71M.

What Is Lyra's Earnings Per Share (TTM)?

The Lyra EPS (TTM) is -60.66.

When Is the Next Lyra Earnings Date?

Lyra will release its next earnings report on 11 Aug 2025.

From a Technical Analysis Perspective, Is LYRA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Lyra Stock Split?

Lyra has split 1 times.

How Many Employees Does Lyra Have?

Lyra has 30 employees.

What is the current trading status of Lyra (LYRA)?

As of 09 Aug 2025, Lyra (LYRA) is trading at a price of 6.70, with a previous close of 6.89. The stock has fluctuated within a day range of 6.56 to 7.08, while its 52-week range spans from 3.81 to 37.50.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.